The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

AACR conference chairs Lillian L. Siu, MD, and Matthew Vander Heiden, MD, PhD, share their perspectives on the event with GEN ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.

DelveInsight's "IBRANCE Market Size, Forecast, and Market Insight Report" highlights the details around IBRANCE, a CDK4/6 inhibitor. The ...

Health system pharmacists and physicians are monitoring a wave of expected new drug approvals between late 2024 and third quarter of 2025. A recent article published in the American Journal of ...

A program cochair said the agenda was designed to get attendees "out of their comfort zone." The Amercian Association for ...

On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Cancer patients invariably develop resistance to targeted drugs, so drugmakers develop strategies to combat it before ...

Enliven Therapeutics is a clinical-stage concern that has two candidates in its pipeline targeting oncology indications.

Dr. Jin noted that ETX-636 is the second novel ENSEM compound entering clinical development. ETX-197, an oral selective CDK2 inhibitor licensed to BeOne and being developed as BG-68501, is currently ...